Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: Risk factors, cytokine use and cost

Bone Marrow Transplantation

Volumn 33, Issue 10, 2004, Pages 997-1003

  Boeve, S ^a   Strupeck, J ^a   Creech, S ^a   Stiff, P J ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autologous stem cell transplants; Hard to mobilize patients; Remobilization

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CYTOKINE; CYTOTOXIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL COUNT; CELL DAMAGE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG USE; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; STEM CELL; STEM CELL MOBILIZATION; TESTIS CANCER; TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, CD34; BLOOD COMPONENT REMOVAL; COHORT STUDIES; CYTOKINES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 2942588568     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704486     Document Type: Article

References (57)

1. Stiff PJ. Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant 1999; 23 (Suppl. 2): S29-S33.
2. Stiff P. Peripheral blood stem cell mobilization: contemporary issues and early studies using Flt3 ligand. In: Rowe J, Lazarus H, Carella A (eds). Handbook of Bone Marrow Transplantation. London: Martin Dunitz Ltd, 2000.
3. Stiff P, Gingrich R, Luger S et al. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 2000; 26: 471-481.
4. Gazitt Y, Freytes CO, Callander N et al. Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization. J Hematother 1999; 8:173-183.
5. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
6. Weaver CH, Potz J, Redmond J et al. Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34 + cell content. Bone Marrow Transplant 1997; 19: 1103-1110.
7. Canales MA, Arrieta R, Hernandez-Garcia MC et al. Factors influencing collection and engraftment of CD34+ cells in patients with breast cancer following high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation. J Hematother Stem Cell Res 2000, 9103-9109.
8. Glaspy JA. Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy. Bone Marrow Transplant 1999; 23 (Suppl 2): S21-7.
9. van der Wall E, Richel DJ, Holtkamp MJ et al. Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size. Ann Oncol 1994; 5: 795-802.
10. Remes K, Matinlauri I, Grenman S et al. Daily measurements of blood CD34+ cells after stem cell mobilization predict stem cell yield and posttransplant hematopoietic recovery. J Hematother 1997; 6: 13-19.
11. Kiss JE, Rybka WB, Winkelstein A et al. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 303-310.
12. Moskowitz CH, Glassman JR, Wuest D et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998; 4: 311-316.
13. Haas R, Mohle R, Fruhauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
14. Ketterer N, Salles G, Moullet I et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 10: 235-242.
15. Sautois B, Fraipont V, Baudoux E et al. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. Haematologica 1999; 84: 342-349.
16. Goldschmidt H, Hegenbart U, Wallmeier M et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736-744.
17. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
18. Shepherd KM, Charles P, Sage RE et al. Mobilization of haemopoietic stem cells by cyclophosphamide into the peripheral blood of patients with haematological malignancies. Clin Lab Haematol 1991; 13: 25-32.
19. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
20. Dreger P, Kloss M, Petersen B et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86: 3970-3978.
21. Vantelon JM, Koscielny S, Brault P et al. Scoring system for the prediction of successful peripheral blood stem cell (PBSC) collection in non-Hodgkin's lymphoma (NHL): application in clinical practice. Bone Marrow Transplant 2000; 25: 495-499.
22. Sugrue MW, Williams K, Pollock BH et al. Characterization and outcome of 'hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2000; 39: 509-519.
23. Kroger N, Zeller W, Hassan HT et al. Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone. Ann Hematol 1998; 76: 257-262.
24. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
25. Prince HM, Imrie K, Sutherland DR et al. Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections. Br J Haematol 1996; 93: 142-145.
26. Visani G, Lemoli RM, Tosi P et al. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol 1999; 105: 775-779.
27. Passos-Coelho JL, Braine HG, Davis JM et al. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte - macrophage colony-stimulating factor mobilization. J Clin Oncol 1995; 13: 705-714.
28. Kroger N, Rauhoft C, Zeller W et al. Efficacy of further attempts to mobilize CD34+ peripheral stem cells with alternative procedures after primary failure. Acta Haematol 2000; 102: 144-147.
29. Weaver CH, Tauer K, Zhen B et al. Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields. J Hematother 1998; 7: 241-249.
30. Martinez C, Urbano-Ispizua A, Marin P et al. Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors. Bone Marrow Transplant 1999; 24: 1273-1278.
31. Grigg AP, Roberts AW, Raunow H et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437-4445.
32. Waller CF, Bertz H, Wenger MK et al. Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimen. Bone Marrow Transplant 1996; 18: 279-283.
33. Stroncek DF, Clay ME, Petzoldt ML et al. Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion 1996; 36: 601-610.
34. Hoglund M, Smedmyr B, Simonsson B et al. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. Bone Marrow Transplant 1996; 18: 19-27.
35. Dreger P, Haferlach T, Eckstein V et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 1994; 87: 609-613.
36. Kobbe G, Sohngen D, Bauser U et al. Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myeloma. Ann Hematol 1999; 78: 456-462.
37. Zeller W, Cassens U, Stockschlader M et al. Higher dose of G-CSF increases yield of mobilized CD34+ cells. Blood 1994; 84 (Suppl 1): 106a.
38. Nademanee A, Sniecinski I, Schmidt GM et al. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 1994; 12: 2176-2186.
39. Zeller W, Gutensohn K, Stockschlader M et al. Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis. Bone Marrow Transplant 1996; 17: 709-713.
40. Engelhardt M, Bertz H, Afting M et al. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. J Clin Oncol 1999; 17: 2160-2172.
41. Weaver CH, Birch R, Greco FA et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol 1998; 100: 338-347.
42. Winter JN, Lazarus HM, Rademaker A et al. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. J Clin Oncol 1996; 14: 277-286.
43. Bashey A, Corringham S, Fields K et al. Use of concurrent GM-CSF and G-CSF administration to re-mobilize patients who fail initial mobilization: results on twenty-three patients from two centers. Blood 1999; 94 (Suppl. 1): 327a.
44. Lane TA, Law P, Maruyama M et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995; 85: 275-282.
45. Madero L, Gonzalez-Vicent M, Molina J et al. Use of concurrent G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells in children with malignant disease. Bone Marrow Transplant 2000; 26: 365-369.
46. Spitzer G, Mathews M, Dunphy F et al. Are growth factor (GF) combinations superior to G-CSF alone for mobilization of peripheral blood stem cells (PBSC): a randomized study comparing G-CSF to G-CSF with GM-CSF for PBSC mobilization. Blood 1994; 84 (Suppl. 1): 107a.
47. Meisenberg B, Brehm T, Schmeckel A et al. A combination of low-dose cyclophosphamide and colony-stimulating factors is more cost-effective than granulocyte-colony-stimulating factors alone in mobilizing peripheral blood stem and progenitor cells. Transfusion 1998; 38: 209-215.
48. Meehan KR, Areman EM, Ericson SG et al. Mobilization, collection, and processing of autologous peripheral blood stem cells: development of a clinical process with associated costs. J Hematother Stem Cell Res 2000; 9: 767-771.
49. Smith TJ, Hillner BE, Schmitz N et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 5-10.
50. Weaver A, Wrigley E, Watson A et al. A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide. Br J Cancer 1996; 74: 1821-1827.
51. Glaspy JA, Shpall EJ, LeMaistre CF et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997; 90: 2939-2951.
52. Andrews RG, Briddell RA, Knitter GH et al. In vivo synergy between recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in baboons enhanced circulation of progenitor cells. Blood 1994; 84: 800-810.
53. Shpall EJ, Wheeler CA, Turner SA et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 1999; 93: 2491-2501.
54. Stiff P, Gingrich R, Luger S et al. Improved PBPC collection using STEMGEN (stem cell factor, SCF) and filgrastim (G-CSF) compared to G-CSF alone in heavily pre-treated lymphoma (NHL) and Hodgkin's disease (HD) patients (pts). Blood 1997; 91 (Suppl. 1): 591a.
55. Chao N, Litzow M, Geller R et al. Randomized phase II study of FLT3 ligand (Mobist) in combination with GM-CSF or G-CSF for mobilization of peripheral blood progenitor cells in patients with breast cancer. Blood 1999; 94: 666a.
56. Stiff P, Beveridge R, Vose J et al. Randomized phase II study of FLT 3 ligand (Mobist) in combination with GM-CSF or G-CSF for mobilization of peripheral blood progenitor cells in patients with lymphoma or ovarian cancer. Blood 1999; 94: 666a.
57. Kuter DJ, Begly CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100: 3457-3469.